Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.

Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.

No treatment is completely effective for alopecia totalis and alopecia universalis.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

Hair loss in elderly women is often caused by various factors, including hormonal changes after menopause.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

Certain scalp patterns can indicate the severity and activity of hair loss in Turkish alopecia patients.

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.

The document concludes that ongoing research using animal models is crucial for better understanding and treating Alopecia Areata.

Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.

Alopecia areata involves immune response and gene changes affecting hair loss.

The study concluded that yellow dots are a common and useful sign for diagnosing alopecia areata in dark-skinned individuals and may indicate the severity of the condition.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

The research suggests that autophagy-related genes might play a role in causing alopecia areata.

The conclusion is that understanding and addressing the psychological effects of alopecia areata is important for effective treatment.

Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.

Non-immune factors play a significant role in alopecia areata.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

High and low doses of prednisolone helped 62% of children with severe alopecia regrow hair with some weight gain and mild acne as side effects.

Switching to twice-weekly betamethasone led to full hair regrowth in 3 months without side effects.